Taysha Gene Therapies Releases TSHA-102 Clinical Program Updates
Details of Taysha Gene Therapies, Inc.
Taysha Gene Therapies Inc. (TSHA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 19,999,999 | $27,799,999 | 0.43% | |
| 2. | RA Capital Management Peter Kolchinsky | 10,872,503 | $15,112,779 | 0.25% | |
| 3. | Octagon Capital Advisors Ting Jia | 10,700,000 | $14,873,000 | +3% | 2.88% |
| 4. | Siren L.L.C. Raymond Debbane | 6,514,737 | $9,055,484 | -2% | 0.51% |
| 5. | Point72 Asset Management Steve Cohen | 4,569,678 | $6,351,852 | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.75 | 750,000 | 2,841,704 | 2025-05-30 | Filing | ||
| $2.25 | 1,333,333 | 1,333,333 | 2024-06-27 | Filing | ||
| $1.63 | 100,000 | Large Shareholder | 16,566,667 | 2023-11-17 | Filing | |
| $0.90 | 16,466,667 | Large Shareholder | 16,466,667 | 2023-08-16 | Filing | |
| $0.90 | 388,889 | Director | 999,381 | 2023-08-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.33 | 33,000 | Officer | 258,042 | 2023-08-24 | Filing | |
| $0.70 | 5,344 | 8,871,747 | 2023-07-13 | Filing | ||
| $0.71 | 80,528 | 8,877,091 | 2023-07-12 | Filing | ||
| $0.70 | 18,100 | Large Shareholder | 8,957,619 | 2023-06-23 | Filing | |
| $0.70 | 10,508 | Large Shareholder | 8,975,719 | 2023-06-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,787,866 | $26,115,134 | 0.4% | |
| 2. | 16,846,374 | $23,416,461 | 0% | |
| 3. | 15,631,954 | $21,728,416 | 0% | |
| 4. | 13,589,178 | $18,888,958 | 0% | |
| 5. | 8,770,921 | $12,191,580 | 0% |
News See All
Needham Lifts Taysha Gene Therapies (TSHA) PT to $8, Cites Positive Clinical Data
On June 2, Needham raised its price target for Taysha Gene Therapies Inc. (NASDAQ:TSHA) to $8 from $6, while maintaining a Buy rating on the stock.
Taysha Gene Therapies (TSHA) Price Target Raised by JMP on Positive Rett Syndrome Trial Data
On May 29, JMP Securities Silvan Tuerkcan revised the firm's view on Taysha Gene Therapies, Inc. (NASDAQ:TSHA), raising the price target from $5 to $6 while keeping a Market Outperform rating.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2025 Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2025 Earnings Call Transcript May 15, 2025Taysha Gene Therapies, Inc. reports earnings inline with expectations.
10 Best Short Squeeze Stocks to Buy According to Analysts
Stock market trading has an ever-changing environment. Short squeeze is among the few phenomena capable of capturing and holding the attention of such markets.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, good morning. And welcome to the Taysha Gene Therapies full year 2024. At this time, all participants are in a listen-only mode.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2024 Earnings Call Transcript
Operator: Greetings. And welcome to the Taysha Gene Therapies’ Third Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.
10 Most Promising Biotech Stocks According to Hedge Funds
Biotechnology stocks are known for their high risk, making them some of the most volatile in the market.
7 Best NASDAQ Stocks Under $5
A Yahoo Finance report on September 28 reveals that consumers are beginning to feel the effects of a cooling labor market, according to the latest Consumer Confidence Index, which shows a narrowing gap...
Billionaire Hedge Funds
